The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice

Nature Communications

Volumn 5, Issue , 2014, Pages

  Sapra, Geeta ^a   Tham, Yow Keat ^a   Cemerlang, Nelly ^a   Matsumoto, Aya ^a   Kiriazis, Helen ^a   Bernardo, Bianca C ^a   Henstridge, Darren C ^a   Ooi, Jenny Y Y ^a   Pretorius, Lynette ^a,b   Boey, Esther J H ^a   Lim, Lydia ^a   Sadoshima, Junichi ^c,d   Meikle, Peter J ^a   Mellet, Natalie A ^a   Woodcock, Elizabeth A ^a   Marasco, Silvana ^a   Ueyama, Tomomi ^e   Du, Xiao Jun ^a   Febbraio, Mark A ^a,b   McMullen, Julie R ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d ALFRED HOSPITAL   (Australia)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CAVEOLIN 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SOMATOMEDIN C RECEPTOR; GANGLIOSIDE GM3; IGF1R PROTEIN, HUMAN; OXIME; PIPERIDINE DERIVATIVE; SOMATOMEDIN RECEPTOR;

GENE EXPRESSION; GROWTH REGULATOR; MOLECULAR ANALYSIS; RISK FACTOR; RODENT; SAMPLING;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; MEMBRANE FLUIDITY; MOUSE; NONHUMAN; PR INTERVAL; PROTEIN PHOSPHORYLATION; ANIMAL; ATRIAL FIBRILLATION; CHEMISTRY; DISEASE MODEL; ELECTROCARDIOGRAPHY; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MICROARRAY ANALYSIS; PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE;

MUS;

ANIMALS; ATRIAL FIBRILLATION; CAVEOLIN 1; CAVEOLIN 3; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; G(M3) GANGLIOSIDE; HEART FAILURE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROARRAY ANALYSIS; OXIMES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTORS, SOMATOMEDIN; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSGENES;

EID: 84923359917     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6705     Document Type: Article

References (67)

1. Go, A. S. et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
2. Braunwald, E. Heart failure. JACC Heart Fail. 1, 1-20 (2013).
3. Savelieva, I. & John Camm, A. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 5(Suppl 1), S5-S19 (2004).
4. Lubitz, S. A., Benjamin, E. J. & Ellinor, P. T. Atrial fibrillation in congestive heart failure. Heart Fail. Clin. 6, 187-200 (2010).
5. Fuster, V. et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 57, e101-e198 (2011).
6. Rienstra, M. et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail. 1, 21-28 (2013).
7. Bristow, M. R. & Aleong, R. G. Treatment of the heart failure patient with atrial fibrillation: a major unmet need. JACC Heart Fail. 1, 29-30 (2013).
8. McManus, D. D., Rienstra, M. & Benjamin, E. J. An update on the prognosis of patients with atrial fibrillation. Circulation 126, e143-e146 (2012).
9. Literati-Nagy, Z. et al. The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics. Cell Stress Chaperones 17, 517-521 (2012).
10. Literati-Nagy, B. et al. Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders. Brain Res. Bull. 83, 340-344 (2010).
11. Literati-Nagy, B. et al. Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial. Horm. Metab. Res. 41, 374-380 (2009).
12. Crul, T. et al. Hydroximic acid derivatives: pleiotropic hsp co-inducers restoring homeostasis and robustness. Curr. Pharm. Des. 19, 309-346 (2013).
13. Radford, N. B. et al. Cardioprotective effects of 70-kDa heat shock protein in transgenic mice. Proc. Natl Acad. Sci. USA 93, 2339-2342 (1996).
14. Mandal, K. et al. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann. Thorac. Surg. 79, 865-871 discussion 871 (2005).
15. St Rammos, K. et al. Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc. Surg. 10, 228-232 (2002).
16. Afzal, A. R. et al. Association of Met439Thr substitution in heat shock protein 70 gene with postoperative atrial fibrillation and serum HSP70 protein levels. Cardiology 110, 45-52 (2008).
17. Yang, M. et al. Expression of heat shock proteins in myocardium of patients with atrial fibrillation. Cell Stress Chaperones 12, 142-150 (2007).
18. Hutter, J. J. et al. Overexpression of heat shock protein 72 in transgenic mice decreases infarct size in vivo. Circulation 94, 1408-1411 (1996).
19. McMullen, J. R. et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 279, 4782-4793 (2004).
20. Pretorius, L. et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175, 998-1009 (2009).
21. Yamamoto, S. et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest. 111, 1463-1474 (2003).
22. Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537-2548 (2000).
23. Wang, T. J. et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292, 2471-2477 (2004).
24. Lip, G. Y. & Varughese, G. I. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int. J. Cardiol. 105, 319-321 (2005).
25. Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271, 840-844 (1994).
26. Wakili, R., Voigt, N., Kaab, S., Dobrev, D. & Nattel, S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest. 121, 2955-2968 (2011).
27. Kato, T., Iwasaki, Y. K. & Nattel, S. Connexins and atrial fibrillation: filling in the gaps. Circulation 125, 203-206 (2012).
28. Cheng, S. et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 301, 2571-2577 (2009).
29. Magnani, J. W. et al. Electrocardiographic PR interval and adverse outcomes in older adults: the Health, Aging, and Body Composition study. Circ. Arrhythm. Electrophysiol. 6, 84-90 (2013).
30. Nielsen, J. B. et al. Risk of atrial fibrillation as a function of the electrocardiographic PR interval: results from the Copenhagen ECG Study. Heart Rhythm 10, 1249-1256 (2013).
31. Gehrig, S. M. et al. Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 484, 394-398 (2012).
32. Chung, J. et al. HSP72 protects against obesity-induced insulin resistance. Proc. Natl Acad. Sci. USA 105, 1739-1744 (2008).
33. Brundel, B. J. et al. Heat shock protein upregulation protects against pacinginduced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J. Mol. Cell Cardiol. 41, 555-562 (2006).
34. Gombos, I. et al. Membrane-lipid therapy in operation: the HSP co-inducer BGP-15 activates stress signal transduction pathways by remodeling plasma membrane rafts. PLoS ONE 6, e28818 (2011).
35. Serneri, G. G. et al. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ. Res. 85, 57-67 (1999).
36. Prokazova, N. V., Samovilova, N. N., Gracheva, E. V. & Golovanova, N. K. Ganglioside GM3 and its biological functions. Biochemistry (Mosc.) 74, 235-249 (2009).
37. Iwamori, M., Shimomura, J., Tsuyuhara, S. & Nagai, Y. Gangliosides of various rat tissues: distribution of ganglio-N-tetraose-containing gangliosides and tissue-characteristic composition of gangliosides. J. Biochem. 95, 761-770 (1984).
38. de Laurentiis, A., Donovan, L. & Arcaro, A. Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem. J. 1, 12-32 (2007).
39. Troncoso, R., Ibarra, C., Vicencio, J. M., Jaimovich, E. & Lavandero, S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab. 25, 128-137 (2014).
40. Ogata, T. et al. MURC, a muscle-restricted coiled-coil protein that modulates the Rho/ROCK pathway, induces cardiac dysfunction and conduction disturbance. Mol. Cell. Biol. 28, 3424-3436 (2008).
41. Rodriguez, G. et al. Molecular genetic and functional characterization implicate muscle-restricted coiled-coil gene (MURC) as a causal gene for familial dilated cardiomyopathy. Circ. Cardiovasc. Genet. 4, 349-358 (2011).
42. ClinicalTrials.gov, NCT01069965. N-Gene research laboratories i safety and efficacy of bgp-15 in patients with type 2 diabetes mellitus http://clinicaltrials.gov/ct2/show/NCT01069965?term=bgp-15&rank=1 (2013).
43. Weeks, K. L. et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5, 523-534 (2012).
44. Whittington, H. J. et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc. Res. 99, 694-704 (2013).
45. Nitta, Y., Abe, K., Aoki, M., Ohno, I. & Isoyama, S. Diminished heat shock protein 70 mRNA induction in aged rat hearts after ischemia. Am. J. Physiol. 267, H1795-H1803 (1994).
46. Kregel, K. C., Moseley, P. L., Skidmore, R., Gutierrez, J. A. & Guerriero, Jr V. HSP70 accumulation in tissues of heat-stressed rats is blunted with advancing age. J. Appl. Physiol. (1985) 79, 1673-1678 (1995).
47. Demirel, H. A. et al. Age and attenuation of exercise-induced myocardial HSP72 accumulation. Am. J. Physiol. Heart Circ. Physiol. 285, H1609-H1615 (2003).
48. McMullen, J. R. Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease. Clin. Exp. Pharmacol. Physiol. 35, 349-354 (2008).
49. Millis, R. M., Alvin, Z. V., Zhao, A. & Haddad, G. E. Effects of IGF-1 on I(K) and I(K1) channels via PI3K/Akt signaling in neonatal cardiac myocytes. Int. J. Cell Biol. 2012, 712153 (2012).
50. Yamashita, T. et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl Acad. Sci. USA 100, 3445-3449 (2003).
51. Larsen, P. J. & Tennagels, N. On ceramides, other sphingolipids and impaired glucose homeostasis. Mol. Metab. 3, 252-260 (2014).
52. Panneerselvam, M., Patel, H. H. & Roth, D. M. Caveolins and heart diseases. Adv. Exp. Med. Biol. 729, 145-156 (2012).
53. Ellinor, P. T. et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature Genet. 44, 670-675 (2012).
54. Dalle, S., Ricketts, W., Imamura, T., Vollenweider, P. & Olefsky, J. M. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 276, 15688-15695 (2001).
55. Hallak, H., Seiler, A. E., Green, J. S., Ross, B. N. & Rubin, R. Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J. Biol. Chem. 275, 2255-2258 (2000).
56. DeGeorge, Jr. B. R. et al. Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 117, 1378-1387 (2008).
57. Kohler, D. et al. Galphai2-and Galphai3-deficient mice display opposite severity of myocardial ischemia reperfusion injury. PLoS ONE 9, e98325 (2014).
58. Zhang, D. et al. Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for atrial fibrillation. J. Mol. Cell. Cardiol. 51, 381-389 (2011).
59. Riley, G., Syeda, F., Kirchhof, P. & Fabritz, L. An introduction to murine models of atrial fibrillation. Front. Physiol. 3, 296 (2012).
60. Kotecha, D. et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet doi:10.1016/S0140-6736(14)61373-8 (2014).
61. Laustsen, P. G. et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell. Biol. 27, 1649-1664 (2007).
62. Szabados, E., Literati-Nagy, P., Farkas, B. & Sumegi, B. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem. Pharmacol. 59, 937-945 (2000).
63. Sarszegi, Z. et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol. Cell. Biochem. 365, 129-137 (2012).
64. Marber, M. S. et al. Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J. Clin. Invest. 95, 1446-1456 (1995).
65. Hunt, C. R. et al. Genomic instability and enhanced radiosensitivity in Hsp70.1-and Hsp70.3-deficient mice. Mol. Cell. Biol. 24, 899-911 (2004).
66. Weir, J. M. et al. Plasma lipid profiling in a large population-based cohort. J. Lipid. Res. 54, 2898-2908 (2013).
67. Bruce, C. R. et al. Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. Diabetes 61, 3148-3155 (2012).